Arca
Skip to content
Tools
Tools

Fallopian tube cancer

Drug research and approvals for fallopian tube cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 122 studies of fallopian tube cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 35 drug trials for it since 2013, and FDA has 3 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 122
  • Trials authorized in Canada: 35
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 122 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 12 of 20

Phase 2 12 of 80

Phase 1 or earlier 12 of 52

How its trials ended

640 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 185 whose ending is known, 28% met their primary endpoint, 15% missed it and 57% stopped early.

  • Completed, result not reported23737%
  • Ongoing16426%
  • Status unknown548%
  • Met its primary endpoint518%
  • Stopped: other or unclear477%
  • Missed its primary endpoint284%
  • Stopped: enrollment or feasibility284%
  • Stopped: sponsor or business decision132%
  • Stopped: funding91%
  • Stopped: lack of efficacy61%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 35; search them all in Canada trials
Sep 23, 2026A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab)Merck & Co. (MSD)Pending
Aug 26, 2026A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / VegzelmaAstraZeneca PharmaceuticalsPending
Aug 20, 2026A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab)AstraZeneca PharmaceuticalsPending
Feb 26, 2026A randomized, open-label phase 3 study of azenosertib versus investigator’s choice of chemotherapy in platinum resistant high-grade serous ovarian, primary…AzenosertibK-Group Beta, Inc.Pending
Dec 23, 2025A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel…Merck & Co. (MSD)Ongoing
Jun 12, 2024A phase 1, first-in-human, open-label, dose-escalation and expansion study of IMGN151 (anti-fr antibody-drug conjugate) in adult patients with recurrent…IMGN151AbbVieOngoing
Jan 18, 2023A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / PaclitaxelCorcept TherapeuticsOngoing
Nov 9, 2022Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansineAbbVieOngoing
Sep 29, 2022Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853)AbbVieOngoing
Feb 11, 2022Piccolo: a phase 2, single arm study of mirvetuximab soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or…Mirvetuximab soravtansine (IMGN853)AbbVieClosed

FDA orphan designations

Approved first, then open designations, newest first
May 8, 2020LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,…AstraZeneca Pharmaceuticals LPApproved
Dec 19, 2018LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic…AstraZeneca Pharmaceuticals LPApproved
Aug 17, 2017LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a…AstraZeneca Pharmaceuticals LPApproved
Mar 2, 2026RezatapoptTreatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancerPMV Pharmaceuticals, Inc.Designated
Aug 27, 2024N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of AT-rich interactive domain-containing protein 1a (ARID1a)-deficient ovarian cancer, fallopian tube cancer, and primary…Nuvectis Pharma, Inc.Designated
Feb 24, 2015PelareorepTreatment of fallopian tube cancerOncolytics Biotech, Inc.Designated
Feb 2, 2010PatupiloneTreatment of primary fallopian tube cancer.Novartis Pharmaceuticals CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.